<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34518579</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>13</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>A microfluidic approach to rescue ALS motor neuron degeneration using rapamycin.</ArticleTitle><Pagination><StartPage>18168</StartPage><MedlinePgn>18168</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">18168</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-97405-1</ELocationID><Abstract><AbstractText>TAR DNA-binding protein-43 (TDP-43) is known to accumulate in ubiquitinated inclusions of amyotrophic lateral sclerosis affected motor neurons, resulting in motor neuron degeneration, loss of motor functions, and eventually death. Rapamycin, an mTOR inhibitor and a commonly used immunosuppressive drug, has been shown to increase the survivability of Amyotrophic Lateral Sclerosis (ALS) affected motor neurons. Here we present a transgenic, TDP-43-A315T, mouse model expressing an ALS phenotype and demonstrate the presence of ubiquitinated cytoplasmic TDP-43 aggregates with&#x2009;&gt;&#x2009;80% cell death by 28&#xa0;days post differentiation in vitro. Embryonic stem cells from this mouse model were used to study the onset, progression, and therapeutic remediation of TDP-43 aggregates using a novel microfluidic rapamycin concentration gradient generator. Results using a microfluidic device show that ALS affected motor neuron survival can be increased by 40.44% in a rapamycin dosage range between 0.4-1.0&#xa0;&#xb5;M.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Chennampally</LastName><ForeName>Phaneendra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Microinstruments and Systems Laboratory, University of Maine, Orono, ME, 04469, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, University of Maine, Orono, ME, 04469, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sayed-Zahid</LastName><ForeName>Ambreen</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Graduate School of Biomedical Sciences and Engineering, University of Maine, Orono, ME, 04469, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, ME, 04609, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soundararajan</LastName><ForeName>Prabakaran</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, ME, 04609, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharp</LastName><ForeName>Jocelyn</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, ME, 04609, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cox</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Graduate School of Biomedical Sciences and Engineering, University of Maine, Orono, ME, 04469, USA. greg.cox@jax.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, ME, 04609, USA. greg.cox@jax.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Scott D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Microinstruments and Systems Laboratory, University of Maine, Orono, ME, 04469, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Biomedical Sciences and Engineering, University of Maine, Orono, ME, 04469, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, University of Maine, Orono, ME, 04469, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Rosemary L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Microinstruments and Systems Laboratory, University of Maine, Orono, ME, 04469, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Biomedical Sciences and Engineering, University of Maine, Orono, ME, 04469, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Electrical and Computer Engineering, University of Maine, Orono, ME, 04469, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS102414</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R15 NS111377</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber><NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Sci Rep. 2021 Sep 29;11(1):19743</RefSource><PMID Version="1">34588612</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044085" MajorTopicYN="Y">Microfluidics</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019076" MajorTopicYN="N">Transgenes</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34518579</ArticleId><ArticleId IdType="pmc">PMC8438029</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-97405-1</ArticleId><ArticleId IdType="pii">10.1038/s41598-021-97405-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2001;344:1688&#x2013;1700.</Citation><ArticleIdList><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco D, et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat. Neurosci. 2010;13:1396&#x2013;1403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2967729</ArticleId><ArticleId IdType="pubmed">20953194</ArticleId></ArticleIdList></Reference><Reference><Citation>Pansarasa O, et al. SOD1 in amyotrophic lateral sclerosis: &#x201c;Ambivalent&#x201d; behavior connected to the disease. Int. J. Mol. Sci. 2018;19:1345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5983710</ArticleId><ArticleId IdType="pubmed">29751510</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, et al. The TDP-43 proteinopathies, toward understanding of the molecular pathogenesis. Rinsho Shinkeigaku. 2009;49:783&#x2013;785.</Citation><ArticleIdList><ArticleId IdType="pubmed">20030209</ArticleId></ArticleIdList></Reference><Reference><Citation>Wroe R, Butler AW-L, Andersen PM, Powell JF, Al-Chalabi A. ALSOD: The amyotrophic lateral sclerosis online database. Amyotroph. Lateral Sc. 2009;9:249&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">18608099</ArticleId></ArticleIdList></Reference><Reference><Citation>Hergesheimer RC, et al. The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: A resolution in sight? Brain J. Neurol. 2019;142:1176&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6487324</ArticleId><ArticleId IdType="pubmed">30938443</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y-J, et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc. Natl. Acad. Sci. USA. 2009;106:7607&#x2013;7612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671323</ArticleId><ArticleId IdType="pubmed">19383787</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura A, et al. Interaction of RNA with a C-terminal fragment of the amyotrophic lateral sclerosis-associated TDP43 reduces cytotoxicity. Sci. Rep.-uk. 2016;6:19230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4725827</ArticleId><ArticleId IdType="pubmed">26757674</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh CW, et al. Chronic oxidative stress promotes GADD34-mediated phosphorylation of the TAR DNA-binding protein TDP-43, a modification linked to neurodegeneration. J. Biol. Chem. 2017;293:163&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5766914</ArticleId><ArticleId IdType="pubmed">29109149</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009;117:137&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xe4;chter N, Storch A, Hermann A. Human TDP-43 and FUS selectively affect motor neuron maturation and survival in a murine cell model of ALS by non-cell-autonomous mechanisms. Amyotroph. Lateral Scler. Frontotemp. Degener. 2015;16:431&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">26174443</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen TJ, et al. An acetylation switch controls TDP-43 function and aggregation propensity. Nat. Commun. 2015;6:5845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4407365</ArticleId><ArticleId IdType="pubmed">25556531</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Wander CM, Yuan C-X, Bereman MS, Cohen TJ. Acetylation-induced TDP-43 pathology is suppressed by an HSF1-dependent chaperone program. Nat. Commun. 2017;8:82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5517419</ArticleId><ArticleId IdType="pubmed">28724966</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaguri H, et al. The extreme N-terminus of TDP-43 mediates the cytoplasmic aggregation of TDP-43 and associated toxicity in vivo. Brain Res. 2016;1647:57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003772</ArticleId><ArticleId IdType="pubmed">27155453</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton MJ, et al. A90V TDP-43 variant results in the aberrant localization of TDP-43 in vitro. FEBS Lett. 2008;582:2252&#x2013;2256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2478749</ArticleId><ArticleId IdType="pubmed">18505686</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hosokawa M, Hasegawa M, Akiyama H, Asada T. A new dementia group caused by TDP-43 abnormality. Seishin Shinkeigaku Zasshi Psychiatria Et Neurologia Japonica. 2011;113:574&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">21815469</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen T, Lee V, Trojanowski J. TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. Trends Mol. Med. 2011;17:659&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202652</ArticleId><ArticleId IdType="pubmed">21783422</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, et al. TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. Acta Neuropathol. 2014;128:423&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4384652</ArticleId><ArticleId IdType="pubmed">24916269</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann. Neurol. 2013;74:20&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenouda M, Zhang A, Weichert A, Robertson J. Mechanisms associated with TDP-43 neurotoxicity in ALS/FTLD. Adv. Neurobiol. 2018;20:239&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">29916022</ArticleId></ArticleIdList></Reference><Reference><Citation>Budini M, Buratti E, Morselli E, Criollo A. Autophagy and its impact on neurodegenerative diseases: New roles for TDP-43 and C9orf72. Front. Mol. Neurosci. 2017;10:170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5447761</ArticleId><ArticleId IdType="pubmed">28611593</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai S-L, et al. FUS mutations in sporadic amyotrophic lateral sclerosis. Neurobiol. Aging. 2011;32(550):e1&#x2013;550.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891336</ArticleId><ArticleId IdType="pubmed">20138404</ArticleId></ArticleIdList></Reference><Reference><Citation>Damme PV, et al. The occurrence of mutations in FUS in a Belgian cohort of patients with familial ALS: FUS mutations in familial ALS. Eur. J. Neurol. 2009;17:754&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">19922450</ArticleId></ArticleIdList></Reference><Reference><Citation>Law WJ, Cann KL, Hicks GG. TLS, EWS and TAF15: A model for transcriptional integration of gene expression. Brief Funct. Genom. 2006;5:8&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">16769671</ArticleId></ArticleIdList></Reference><Reference><Citation>Sama RRK, Ward CL, Bosco DA. Functions of FUS/TLS from DNA repair to stress response: Implications for ALS. ASN Neuro. 2014;6:1759091414544472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4189536</ArticleId><ArticleId IdType="pubmed">25289647</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratti A, Buratti E. Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins. J. Neurochem. 2016;138:95&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">27015757</ArticleId></ArticleIdList></Reference><Reference><Citation>Ederle H, et al. Nuclear egress of TDP-43 and FUS occurs independently of Exportin-1/CRM1. Sci. Rep.-uk. 2018;8:7084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935713</ArticleId><ArticleId IdType="pubmed">29728564</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyzack GE, et al. Widespread FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis. Brain. 2019;142:2572&#x2013;2580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6735815</ArticleId><ArticleId IdType="pubmed">31368485</ArticleId></ArticleIdList></Reference><Reference><Citation>McGoldrick P, Joyce PI, Fisher EMC, Greensmith L. Rodent models of amyotrophic lateral sclerosis. Biochim. Biophys. Acta Bba Mol. Basis Dis. 2013;1832:1421&#x2013;1436.</Citation><ArticleIdList><ArticleId IdType="pubmed">23524377</ArticleId></ArticleIdList></Reference><Reference><Citation>Norman GAV. Limitations of animal studies for predicting toxicity in clinical trials is it time to rethink our current approach? Jacc Basic Transl. Sci. 2019;4:845&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6978558</ArticleId><ArticleId IdType="pubmed">31998852</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, et al. Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial) Medicine. 2018;97:e11119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6024184</ArticleId><ArticleId IdType="pubmed">29901635</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, et al. Rapamycin treatment augments motor neuron degeneration in SOD1 G93A mouse model of amyotrophic lateral sclerosis. Autophagy. 2011;7:412&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">21193837</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Guan K-L. mTOR as a central hub of nutrient signalling and cell growth. Nat. Cell. Biol. 2019;21:63&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">30602761</ArticleId></ArticleIdList></Reference><Reference><Citation>Laplante M, Sabatini DM. mTOR signaling at a glance. J. Cell Sci. 2009;122:3589&#x2013;3594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758797</ArticleId><ArticleId IdType="pubmed">19812304</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;169:361&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">28388417</ArticleId></ArticleIdList></Reference><Reference><Citation>Dossou AS, Basu A. The emerging roles of mTORC1 in macromanaging autophagy. Cancers. 2019;11:1422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6826502</ArticleId><ArticleId IdType="pubmed">31554253</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballou LM, Lin RZ. Rapamycin and mTOR kinase inhibitors. J. Chem. Biol. 2008;1:27&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2698317</ArticleId><ArticleId IdType="pubmed">19568796</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Kim SG, Blenis J. Rapamycin: One drug, many effects. Cell Metab. 2014;19:373&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3972801</ArticleId><ArticleId IdType="pubmed">24508508</ArticleId></ArticleIdList></Reference><Reference><Citation>Settembre C, et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. Embo J. 2012;31:1095&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3298007</ArticleId><ArticleId IdType="pubmed">22343943</ArticleId></ArticleIdList></Reference><Reference><Citation>Osaki T, Uzel SGM, Kamm RD. Microphysiological 3D model of amyotrophic lateral sclerosis (ALS) from human iPS-derived muscle cells and optogenetic motor neurons. Sci. Adv. 2018;4:5847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6179377</ArticleId><ArticleId IdType="pubmed">30324134</ArticleId></ArticleIdList></Reference><Reference><Citation>Dertinger SKW, Chiu DT, Jeon NL, Whitesides GM. Generation of gradients having complex shapes using microfluidic networks. Anal. Chem. 2001;73:1240&#x2013;1246.</Citation></Reference><Reference><Citation>Demers CJ, et al. Development-on-chip: In vitro neural tube patterning with a microfluidic device. Dev. Camb. Engl. 2016;143:1884&#x2013;1892.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4920155</ArticleId><ArticleId IdType="pubmed">27246712</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RL, Demers CJ, Collins SD. Microfluidic device for the combinatorial application and maintenance of dynamically imposed diffusional gradients. Microfluid Nanofluid. 2010;9:613&#x2013;622.</Citation></Reference><Reference><Citation>Jeon NL, et al. Neutrophil chemotaxis in linear and complex gradients of interleukin-8 formed in a microfabricated device. Nat. Biotechnol. 2002;20:826&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pubmed">12091913</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo S-J, Yao D-J. Get to understand more from single-cells: Current studies of microfluidic-based techniques for single-cell analysis. Int. J. Mol. Sci. 2015;16:16763&#x2013;16777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4581168</ArticleId><ArticleId IdType="pubmed">26213918</ArticleId></ArticleIdList></Reference><Reference><Citation>Thoma CR, Zimmermann M, Agarkova I, Kelm JM, Krek W. 3D cell culture systems modeling tumor growth determinants in cancer target discovery. Adv. Drug Deliv. Rev. 2014;69:29&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">24636868</ArticleId></ArticleIdList></Reference><Reference><Citation>Osaki T, Uzel S, Kamm R. On-chip 3D neuromuscular model for drug screening and precision medicine in neuromuscular disease. Nat. Protoc. 2020;15:421&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">31932771</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Ederle H, Dormann D. TDP-43 and FUS en route from the nucleus to the cytoplasm. Febs Lett. 2017;591:1489&#x2013;1507.</Citation><ArticleIdList><ArticleId IdType="pubmed">28380257</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhardt MF, et al. A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol. Cell. Neurosci. 2013;56:355&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4772428</ArticleId><ArticleId IdType="pubmed">23891805</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzog JJ, et al. TDP-43 dysfunction restricts dendritic complexity by inhibiting CREB activation and altering gene expression. Proc. Natl. Acad. Sci. 2020;117:11760&#x2013;11769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7260973</ArticleId><ArticleId IdType="pubmed">32393629</ArticleId></ArticleIdList></Reference><Reference><Citation>Nijssen J, Comley LH, Hedlund E. Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis. Acta Neuropathol. 2017;133:863&#x2013;885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5427160</ArticleId><ArticleId IdType="pubmed">28409282</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik R, Wiedau M. Therapeutic approaches targeting protein aggregation in amyotrophic lateral sclerosis. Front. Mol. Neurosci. 2020;13:98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7296057</ArticleId><ArticleId IdType="pubmed">32581709</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen C, Teng Y. Is it time to start transitioning from 2D to 3D cell culture? Front. Mol. Biosci. 2020;7:33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7067892</ArticleId><ArticleId IdType="pubmed">32211418</ArticleId></ArticleIdList></Reference><Reference><Citation>Uzel SGM, et al. Microfluidics: Simultaneous or sequential orthogonal gradient formation in a 3D cell culture microfluidic platform (Small 5/2016) Small. 2016;12:688&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4752442</ArticleId><ArticleId IdType="pubmed">26619365</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano NH, Lampe KJ, Xu H, Ferreira MM, Heilshorn SC. Microfluidic gradients reveal enhanced neurite outgrowth but impaired guidance within 3D matrices with high integrin ligand densities. Small. 2015;11:722&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4528974</ArticleId><ArticleId IdType="pubmed">25315156</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamei K, et al. 3D printing of soft lithography mold for rapid production of polydimethylsiloxane-based microfluidic devices for cell stimulation with concentration gradients. Biomed. Microdev. 2015;17:36.</Citation><ArticleIdList><ArticleId IdType="pubmed">25686903</ArticleId></ArticleIdList></Reference><Reference><Citation>Wichterle H, Lieberam I, Porter JA, Jessell TM. Directed differentiation of embryonic stem cells into motor neurons. Cell. 2002;110:385&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">12176325</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim Y-J, et al. 2i Maintains a naive ground state in ESCs through two distinct epigenetic mechanisms. Stem Cell Rep. 2017;8:1312&#x2013;1328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5425728</ArticleId><ArticleId IdType="pubmed">28457889</ArticleId></ArticleIdList></Reference><Reference><Citation>Wichterle H, Peljto M. Differentiation of mouse embryonic stem cells to spinal motor neurons. Curr. Protoc. Stem Cell Biol. 2008;5:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18770634</ArticleId></ArticleIdList></Reference><Reference><Citation>Ungrin MD, Joshi C, Nica A, Bauwens C, Zandstra PW. Reproducible, ultra high-throughput formation of multicellular organization from single cell suspension-derived human embryonic stem cell aggregates. PLoS ONE. 2008;3:e1565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2215775</ArticleId><ArticleId IdType="pubmed">18270562</ArticleId></ArticleIdList></Reference><Reference><Citation>Behringer R, Gertsenstein M, Nagy KV, Nagy A. Differentiating mouse embryonic stem cells into embryoid bodies by hanging-drop cultures. Cold Spring Harb. Protoc. 2016;2016:92429.</Citation><ArticleIdList><ArticleId IdType="pubmed">27934689</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>